key: cord-0723612-qthjm56t
authors: Pereira, Victoria de Carvalho; de Stefani, Douglas Zucolotto; Braga, Arthur Gomes Oliveira; Domingues, Jennyfer Fernanda Rodrigues; Junior, Amilton dos Santos; Dalgalarrondo, Paulo; Banzato, Claudio E.M.
title: Late-onset clozapine-induced agranulocytosis associated with Covid-19: Letter to the Editor
date: 2021-08-14
journal: Psychiatry Res
DOI: 10.1016/j.psychres.2021.114171
sha: edf7a330b5065c60ed701cde939eb9c2da9c61b7
doc_id: 723612
cord_uid: qthjm56t

nan

Three decades after its relaunching, clozapine remains the pharmacological mainstay for treating refractory schizophrenia. Despite that, it is still largely underprescribed because of the fear of its severe adverse effects, especially the hematological ones, such as agranulocytosis (Wiciński & Węclewicz, 2018; Gee & Taylor, 2021; Dragoi et al., 2020) .

The coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first described in Wuhan, China, and rapidly became a pandemic. Initially thought of as a respiratory disease, it is currently considered an infection that involves multiple systems and may lead to a cytokine storm (Terpos et al., 2020) .

The authors describe the case of a patient with schizophrenia, in use of clozapine for 14 years, who developed late-onset agranulocytosis induced by clozapine and at the same time tested positive for SARS-CoV-2. The patient did not present respiratory symptoms and had a full speedy recovery of agranulocytosis with the suspension of clozapine.

A Caucasian 52-year-old male was diagnosed with schizophrenia in his early twenties, with a poor response to several antipsychotics. In 2007, clozapine was prescribed, with a gradual titration until 500mg/day, when the positive symptoms remitted. In 2018, there was another dose increase, to 600mg/day, because mystic religious delusions reemerged.

In April 2017, the full blood count revealed thrombocytopenia, leading to a folic acid 5mg/day prescription. The patient was also using atenolol 25mg/day, due to tachycardia, since November 2020.

Even in the pandemic, his blood counts were monitored monthly, remaining at baseline, with the following white cell counts in February 2021: total white blood cell count (WBC)=4,200/µL, absolute neutrophils count (ANC)=3,000/µL, total lymphocytes count (TLC)=1,200/µL. His platelets were around 160,000/µL.

On March 3 rd , 2021, he developed mild blood dyscrasia: WBC=2,500/µL, ANC=1,981/µL, and TLC=794/µL. Subsequent full blood counts became normal until April 16 th , when he developed leucopenia, with both neutropenia, lymphopenia, leading to a clozapine prescription reduction to 500mg/day. As the parameters kept declining, on May 5th, the clozapine prescription was further decreased to 400mg/day, and haloperidol 2,5mg/day was introduced. On May 12 th , the counts were: WBC=1700/µL, ANC=690/µL, and TLC=500/µL, and there was another reduction in clozapine dose, to 200mg/day, together with an increase of haloperidol, to 5mg/day. Five days later, he developed agranulocytosis, achieving the nadir of WBC=1,400/µL, ANC=277/µL, and TLC=819/µL, which lead to the suspension of clozapine, the increase of haloperidol to 7,5mg/day, and the execution of an infectious screening. The investigation included the reverse transcription-polymerase chain reaction (RT-PCR) test for Sars-Cov-2, which had a positive result.

The patient had had brief contact with a COVID-19 diagnosed person seven days earlier and was asymptomatic. Therefore, we decided to hospitalize the patient in a COVID ward, where both psychiatric and hematological teams were responsible for him, opting for expectant conduct, monitoring his vital signs and inflammatory indicators, which stood normal throughout the period. There were no other infectious agents.

After the suspension of clozapine, his white cell parameters gradually and steadily normalized. On May 31 st , they were: WBC=3,500/µL, ANC=2,076/µL, and TLC=973/µL. The patient remained asymptomatic with normal vital signs and no clinical signs of infections. He also had no rebound psychotic symptoms after the clozapine suspension.

The definition of granulocytopenia (CIAG) and clozapine-induced agranulocytosis is ANC<1500 and ANC<500, with risks of 3% and 0,8% (Wiciński & Węclewicz, 2018) , respectively. The pathophysiology of the CIAG is not entirely understood, but it may occur due to the selective neutrophil toxicity of the clozapine metabolites: clozapine-N-oxide (CNO) and active-Ndesmethylclozapine (NDMC) ( Wiciński & Węclewicz, 2018; Dragoi et al., 2020) . The nitrenium ion is a reactive oxygen species formed by the dehydrogenation of the piperazine-ring of either NDMC, CNO, or clozapine itself (Wiciński & Węclewicz, 2018) . Its synthesis occurs by CYP3A4, CYP2D6, and myeloperoxidase system in white blood cells (Dragoi et al., 2020) , and it ligates to the sulfhydryl groups of proteins in cell membranes, causing an immunemediated response against haptenized neutrophils (Wiciński & Węclewicz, 2018) . The CIAG is most common in the first 18 weeks of treatment and, after one year, the risk is only 0,13% (Wiciński & Węclewicz, 2018; Gee & Taylor, 2021) . This case is unique due to its late onset, 14 years after the beginning of clozapine treatment, combined with the co-occurring diagnosis of COVID-19.

The effects of COVID-19 on patients using clozapine are not well established (Rendon-Quintero et al., 2021) . The Sars-Cov-2 enters the cell after binding to the angiotensin-converting enzyme 2 (ACE2) receptors, found in the lymphocyte's membrane, leading to apoptosis. Besides, a cytokine storm can also lead to apoptosis, so lymphopenia is well established and related to more severe cases, like those with thrombocytopenia and leucopenia. Also, acute respiratory distress syndrome (ARDS) is related to neutrophilia, and data on neutropenia are sparse (Terpos et al., 2020) .

A study conducted in London showed mild and transient neutropenia in the acute phase of COVID-19, not observed in patients that do not use clozapine (Gee & Taylor, 2021) . Evidence suggests that COVID-19 could lead to clozapine toxicity by escalating its serum concentration (Gee & Taylor, 2021; Dragoi et al., 2020) , and these patients are at higher risk of pneumonia and other comorbidities (Dragoi et al., 2020; Rendon-Quintero et al., 2021) . Patients with schizophrenia are more susceptible to COVID-19 due to poor self-care, raised risk of pneumonia, and comorbidities. An outbreak in a Colombian psychiatric clinic shows that many patients could remain asymptomatic (Rendon-Quintero et al., 2021) like the patient described above.

In the reported case, the neutropenia was induced by clozapine and probably aggravated by COVID-19, explaining the pronounced lymphopenia also observed. This rare case of late-onset CIAG occurred in a patient using clozapine for 14 years without previous blood dyscrasias. The concomitant COVID 19 infection, though otherwise asymptomatic, could have led to an exacerbation in the decline of the ANC, resulting in agranulocytosis due to higher serum levels of clozapine or mechanisms intrinsic to the virus. As far as we know, this is the first report of late-onset agranulocytosis co-occurring with COVID-19, and the patient had full and swift hematological recovery with the suspension of clozapine.

Clozapine: An updated overview of pharmacogenetic biomarkers, risks, and safety-particularities in the context of COVID-19

COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine

Schizophrenia in the midst of a COVID-19 outbreak in a psychiatric hospital in Colombia

Hematological findings and complications of COVID-19

Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring

Campinas, August 06, 2021.

The authors declare no conflicts of interest. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication.Victoria de Carvalho Pereira, Douglas Zucolotto de Stefani, Arthur Gomes Oliveira Braga, Jennyfer Fernanda Rodrigues Domingues, Amilton dos Santos Júnior, Paulo Dalgalarrondo and Cláudio E. M. Banzato.